Loading clinical trials...

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.

NCT00143026•Novartis

View on ClinicalTrials.gov

Summary

Detailed Description

This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor fluctuations. Treatment with carbidopa/levodopa/entacapone will be compared with treatment with standard formulation levodopa/carbidopa.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical diagnosis of idiopathic Parkinson's disease exhibiting at least 2 or 3 symptoms
•Motor functions must be regarded as non-disabling by the patient

Exclusion Criteria

•History, signs or symptoms suggesting the diagnosis of atypical or secondary parkinsonism
•History of dyskinesia
•Previous or current use of entacapone or tolcapone
•Unstable Parkinson's disease patients requiring/receiving regimens of levodopa
•Subjects taking levodopa/DDCI controlled release or extended release formulations

Locations (18)

Royal Adelaide Hospital

Adelaide, Australia

Watkins Medical Center

Brisbane, Australia

Central Coast Neuroscience Research

Gosford, Australia

Heidelberg Repatriation Hospital

Melbourne, Australia

Monash Medical Centre

Melbourne, Australia

Sir Charles Gairdner Hospital

Perth, Australia

Concord Hospital

Sydney, Australia

Southern Neurology, St. George Private Hospital

Sydney, Australia

Westmead Hospital

Sydney, Australia

St. Luke's Medical Centre

Manila, Philippines

Key Dates

Start Date

July 1, 2005

Primary Completion Date

June 1, 2006

Completion Date

June 1, 2006

Last Updated

March 29, 2017

Enrollment

184

ACTUAL participants

Conditions

Parkinson's Disease

Interventions

carbidopa, levodopa, entacapone

DRUG

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 29, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Inclusion Criteria

Exclusion Criteria

Deep Brain Stimulation Therapy in Movement Disorders

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations